Theravance Biopharma, Inc.
TBPH
$14.30
$0.130.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.75% | 6.10% | 6.77% | 7.49% | 3.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.75% | 6.10% | 6.77% | 7.49% | 3.69% |
| Cost of Revenue | 5.38% | 27.70% | 13.71% | 11.51% | 5.61% |
| Gross Profit | 265.06% | -28.89% | 0.53% | 2.95% | -0.51% |
| SG&A Expenses | 8.06% | 9.72% | 16.73% | 4.54% | -11.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.07% | 15.99% | 15.69% | 6.91% | -5.90% |
| Operating Income | 78.63% | -28.79% | -39.46% | -5.88% | 14.71% |
| Income Before Tax | 580.95% | -35.92% | -78.21% | -32.56% | -7.29% |
| Income Tax Expenses | 1,304.51% | -144.29% | 88.55% | 93.56% | -10.29% |
| Earnings from Continuing Operations | 431.75% | -16.42% | -82.46% | -41.88% | -5.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 431.75% | -16.42% | -82.46% | -41.88% | -5.65% |
| EBIT | 78.63% | -28.79% | -39.46% | -5.88% | 14.71% |
| EBITDA | 81.21% | -30.13% | -41.47% | -6.22% | 10.18% |
| EPS Basic | 422.26% | -13.08% | -82.87% | -51.49% | -22.86% |
| Normalized Basic EPS | 679.66% | -32.10% | -66.62% | -19.56% | -9.62% |
| EPS Diluted | 417.65% | -13.08% | -82.87% | -51.49% | -23.19% |
| Normalized Diluted EPS | 673.43% | -32.10% | -66.62% | -19.56% | -9.62% |
| Average Basic Shares Outstanding | 2.93% | 2.95% | -0.22% | -6.35% | -14.00% |
| Average Diluted Shares Outstanding | 4.06% | 2.95% | -0.22% | -6.35% | -14.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |